Neuroimmunophilin ligands in the treatment of Parkinson's disease

Current Opinion in Pharmacology

Volumn 2, Issue 1, 2002, Pages 82-86

  Gold, Bruce G ^a,b   Nutt, John G ^c  

^a Ctr Res Occup Environ Toxicol   (United States)

^b Department of Cell and Developmental Biology ^*  (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AMPHETAMINE; ANTIOXIDANT; ANTIPARKINSON AGENT; APOPTOSIS INHIBITOR; CYCLOPHILIN; CYCLOSPORIN A; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR ANTAGONIST; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; LIGAND; LIPID PEROXIDASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE A INHIBITOR; NEUROIMMUNOPHILIN LIGAND DERIVATIVE; NEUROPROTECTIVE AGENT; NEUROTROPHIN; OXIDOPAMINE; PROTEIN C JUN; RAPAMYCIN; SELEGILINE; STEROID RECEPTOR; TSUKUBAENOLIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 10 367; V 10367;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG SCREENING; DYSKINESIA; HUMAN; METABOLISM; NERVE CELL; NEUROPROTECTION; NONHUMAN; ON OFF PHENOMENON; PARKINSON DISEASE; PRIMATE; PROPHYLAXIS; SHORT COURSE THERAPY; SYMPTOMATOLOGY; TRANSPLANTATION; TREATMENT FAILURE; REVIEW;

ANIMALS; HUMANS; IMMUNOPHILINS; LIGANDS; NEURONS; PARKINSON DISEASE;

EID: 0036462452     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00125-4     Document Type: Review

References (51)

1. Parkinson's disease. First of two parts
2. Dopaminergic neurons protected from degeneration by GDNF gene therapy
3. Functional recovery in GDNF-treated parkinsonian monkeys
4. Glial cell line-derived neurotropic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesions
5. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
6. Intraventricular administration of GDNF in the treatment of Parkinson's disease
7. Transplantation of embryonic dopamine neurons for severe Parkinson's disease
8. Neuroimmunophilin ligands and the role of steroid hormone chaperone proteins in nerve regeneration
9. FK506 and the role of the immunophilin FKBP-52 in nerve regeneration
10. Immunophilins in the nervous system
11. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve
12. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury
13. Oral administration of a nonimmunosuppressant FKBP-12 ligand speeds nerve regeneration
14. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration
15. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A
16. Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in rat sciatic nerve
17. FK506 accelerates axonal regeneration through an artificial nerve guide in the rat sciatic nerve transection model
18. FK506 accelerates functional recovery following nerve grafting in a rat model
19. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: Neuroprotection and local regeneration
20. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats
21. Immunosuppressants promote adult dorsal root regeneration into the spinal cord
22. FK506 increases the regeneration of spinal cord axons in a predegenerated peripheral nerve autograft
23. A novel immunophilin ligand: Distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease
24. FK506 produces regeneration, but not neuroprotection, of nigrostriatal dopaminergic neurons in MPTP-treated mice
25. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models
26. Neuroimmunophilin ligands: Evaluation of their therapeutic potential for the treatment of neurological disorders
27. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice
28. FKBP12-binding domain of analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of Parkinson's disease
29. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment
30. +-induced SH-SY5Y apoptosis is potentiated by cyclosporin A and inhibited by aristolochic acid
31. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture
32. Asymmetric retraction of growth cone filopodia following focal inactivation of calcineurin
33. FK506 and the role of immunophilins in nerve regeneration
34. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons
35. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506
36. Guilford Pharmaceuticals announces completion of NIL-A phase II clinical trial for Parkinson's disease
37. Immunophilin ligands can prevent can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease
38. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: Implications for Parkinson's disease
39. Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity
40. The Ras-ERK pathway is required for the induction of neuronal nitric oxide synthase in differentiating PC12 cells
41. Activity and expression of JNK1, p38 and ERK kinses, c-Jun N-terminal phosphorylation, and c-jun promoter binding in the adult rat brain following kainate-induced seizures
42. The immunophilin ligand FK506, but not GPI-1046, protects against neuronal death and inhibits c-jun expression in the substantia nigra pars compacta following transection of the rat medial forebrain bundle
43. MAP kinase phosphatase 1 is expressed and enchanced by FK506 in surviving mamillary, but not degenerating nigral neurons following axotomy
44. The small molecule FKBP ligand GPI 1046 induces partial striatal reinnervation after intranigral 6-hydroxydopamine lesion in rats
45. FK506 and cyclosporin A enchance the survival of cultured and grafted rat embryonic dopamine neurons
46. Effects of immunosuppressive treatment on host responses against intracerebral porcine neural tissue xenografts in rats
47. Transplantation of embryonic porcine mesencephalic tissue in patients with PD
48. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy of transplanted fetal porcine ventral mesencephalic cells versus imitation surgery in patients with Parkinson's disease
49. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease
50. Neuroimmunophilin ligand enchances neurite outgrowth and effect of fetal dopamine transplants
51. Systemic administration of the immunophilin ligand GPI 1046 in MPTP- Treated monkeys